Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025. The US Food and Drug Administration (FDA) has granted Fast ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

The Cascade Theatre announced it's bringing back its annual holiday show, "A Cascade Christmas" on Nov. 21-23 and Nov. 28-30. This year's show follows the misadventures of three elves who accidentally ...

In breaking out a new sweater for the 2026 Winter Classic, the New York Rangers didn’t stray too far from their popular Centennial jersey, which was introduced before the start of this seasons, their ...

This unassuming restaurant with its distinctive burgundy exterior has become a destination dining spot that Oregonians willingly burn gas to reach, regardless of which corner of the state they call ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...

Performances in N.Y.C. Advertisement Supported by The male soprano Samuel Mariño’s “Lumina,” a suite from Thomas Adès’s “The Tempest” and Ginastera’s string quartets are among the highlights. Samuel ...